The FDA has approved Zynyz as a first-line treatment in combination with chemo and as a single-agent following progression in ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

These drugs target some of the most pressing cancer types, including multiple myeloma, breast cancer, and bladder cancer ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today ...

Chugai Pharma seeks Japanese additional indication approval for Tecentriq to treat thymic carcinoma: Tokyo Thursday, May 15, 2025, 12:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd., ...

Studies show that up to 70% of sleep apnea cases may go undiagnosed when home sleep tests rely solely on indirect signals ...